Need help finding what you are looking for?
Contact Us
PUBLISHER: FirstWord Group | PRODUCT CODE: 1272857
PUBLISHER: FirstWord Group | PRODUCT CODE: 1272857
Breast Cancer - Triple Negative - KOL Insight
PUBLISHED:
PAGES:
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
What's exciting oncologists in triple-negative cancer therapy? What clinical benefits do KOLs cite for AstraZeneca/Daiichi Sankyo's pipeline datopotamab deruxtecan and why will the readouts of the BEGONIA trial be significant? Why do experts believe the mechanism of action of G1 Therapeutics' late-stage CDK4/CDK6 inhibitor Cosela could lead to improved outcomes? KOLs critically assess the prospects of launched and pipeline therapies.
In addition to the full report, licensed users have access to the Report Highlights slidedeck and KOL Bulletins via the attachments area.
Table of Contents
Executive summary
Triple-negative breast cancer current and future treatment algorithm
Research objectives
Triple-negative breast cancer
- Marketed drugs
- Lynparza (olaparib; AstraZeneca/Merck & Co.)
- Talzenna (talazoparib; Pfizer)
- Tecentriq (atezolizumab; Roche)
- Keytruda (pembrolizumab; Merck & Co.)
- Trodelvy (sacituzumab govitecan; Gilead Sciences)
- Enhertu (trastuzumab deruxtecan; AstraZeneca/Daiichi Sankyo)
- Pipeline drugs
- Bavencio (avelumab; Merck Group)
- veliparib (ABT-888; AbbVie)
- Zejula (niraparib; GlaxoSmithKline)
- ipatasertib (Roche) and capivasertib (AstraZeneca)
- Piqray (alpelisib; Novartis)
- Cosela (trilaciclib; G1 Therapeutics)
- datopotamab deruxtecan (AstraZeneca/Daiichi Sankyo)
- General future trends impacting treatment
- Key insights summary
Appendix
- KOL details
- KOLs from North America
- KOLs from Europe
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.